MEDNAX (MD) Given a $58.00 Price Target by Jefferies Group Analysts

Jefferies Group set a $58.00 price objective on MEDNAX (NYSE:MD) in a report issued on Thursday morning. The brokerage currently has a hold rating on the stock.

MD has been the topic of a number of other reports. TheStreet raised MEDNAX from a c+ rating to a b rating in a report on Monday. Stephens set a $62.00 target price on MEDNAX and gave the stock a buy rating in a report on Thursday, February 8th. Zacks Investment Research raised MEDNAX from a hold rating to a buy rating and set a $60.00 target price on the stock in a report on Tuesday, January 23rd. JPMorgan Chase & Co. lifted their target price on MEDNAX from $46.00 to $55.00 and gave the stock a neutral rating in a report on Monday, February 12th. Finally, Stifel Nicolaus reaffirmed a hold rating and issued a $56.00 target price on shares of MEDNAX in a report on Wednesday, January 24th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $55.58.

MEDNAX (NYSE:MD) traded down $0.01 during trading hours on Thursday, reaching $57.46. The company’s stock had a trading volume of 313,458 shares, compared to its average volume of 949,651. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $5,379.17, a PE ratio of 16.66, a PEG ratio of 1.42 and a beta of 0.26. MEDNAX has a twelve month low of $40.56 and a twelve month high of $70.72.

MEDNAX (NYSE:MD) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.87 EPS for the quarter, beating the Zacks’ consensus estimate of $0.83 by $0.04. The business had revenue of $910.82 million for the quarter, compared to analysts’ expectations of $884.55 million. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the firm earned $1.00 earnings per share. research analysts forecast that MEDNAX will post 4.03 EPS for the current year.

In related news, insider John C. Pepia sold 3,000 shares of MEDNAX stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $58.35, for a total value of $175,050.00. Following the completion of the transaction, the insider now owns 39,716 shares in the company, valued at $2,317,428.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.40% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fuller & Thaler Asset Management Inc. purchased a new stake in shares of MEDNAX in the third quarter valued at approximately $103,000. Meiji Yasuda Asset Management Co Ltd. boosted its holdings in shares of MEDNAX by 45.3% in the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,230 shares of the company’s stock valued at $226,000 after purchasing an additional 1,630 shares during the period. Delta Capital Management LLC purchased a new stake in shares of MEDNAX in the fourth quarter valued at approximately $227,000. Brown Advisory Inc. purchased a new stake in shares of MEDNAX in the fourth quarter valued at approximately $231,000. Finally, YHB Investment Advisors Inc. purchased a new stake in shares of MEDNAX in the fourth quarter valued at approximately $235,000. Institutional investors own 98.53% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Analyst Recommendations for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with's FREE daily email newsletter.

Leave a Reply